We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Point-of-Care Hemoglobin Testing Compared with Laboratory Analyzer

By LabMedica International staff writers
Posted on 28 Jan 2014
Hemoglobin concentration is assessed to detect anemia and its associated morbidities and is usually determined from venous or capillary blood samples run on a laboratory analyzer.

The blood sample method requires a needle stick and results can be delayed, and exposes caregivers to risks associated with needle sticks and blood exposure. More...
Noninvasive hemoglobin determination would be of benefit to patients and caregivers because it would allow for quick and painless point-of-care assessment.

Clinical scientists at Long Beach Veterans Administration Healthcare System (CA, USA) enrolled 474 subjects in a study to compare a noninvasive hemoglobin concentration measurement method with the traditional technique. A noninvasive hemoglobin (SpHb) test device was placed on the subject's nondominant ring finger. The sensor was covered with an opaque shield to prevent optical interference. A noninvasive hemoglobin measurement was obtained from each subject. Perfusion index, finger temperature, and oxygen saturation (SpO2), measured by the noninvasive hemoglobin test device, were also recorded.

Immediately following the noninvasive testing, a venous blood sample was obtained and analyzed for reference hemoglobin value (Hb) with a laboratory hematology analyzer (LH 500, Beckman Coulter; Brea, CA, USA). A capillary blood sample was also obtained by finger stick within 15 minutes of the noninvasive reading and the venous sample and analyzed immediately with a HemoCue 201 point-of-care hemoglobinometer (Cypress, CA, USA). The noninvasive hemoglobin (SpHb) test device was the Pronto-7, version 2.19, with a rainbow 4D sensor, rev E, (Masimo Corp., Irvine, CA, USA).

The reference hemoglobin concentration ranged from 8.6 g/dL to 17.4 g/dL. Analysis of data from all subjects showed a bias ± standard deviation of −0.1 ± 1.1 g/dL for Pronto-7 SpHb and −0.1 ± 1.6 g/dL for HemoCue, compared with the hematology analyzer. SpHb could be used to safety screen between 73% and 95% of the population to rule out anemia, with SpHb values of ≥11.5g/dL to 13 g/dL and an additional 0.5% of the population to rule in anemia, with SpHb values of 7.5g/dL to ≤10 g/dL.

The authors concluded that their study shows noninvasive hemoglobin measurement with SpHb offers similar accuracy as another established point-of-care method, HemoCue, in an outpatient clinic environment. Its noninvasive and quick testing characteristics may translate into added benefits to patient care. The study was published on January 13, 2014, in the International Journal of Laboratory Hematology.

Related Links:

Long Beach Veterans Administration Healthcare System
Beckman Coulter
Masimo Corp.



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.